Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Stays Upbeat Amid Skepticism On Tiragolumab’s Chances

Confirms Trial Weighted Towards Overall Survival Endpoint

Executive Summary

Analysts are keen to know more about the statistical weighting of Roche’s SKYSCRAPER 1 study of the TIGIT inhibitor, while Merck & Co can learn from their rival’s slip-up for their own trial design.

You may also be interested in...



Roche Is ‘Aiming For The Sky’ With Vabysmo Commercial Launch

CEO Severin Schwan compared his enthusiasm for the newly launched eye drug to Ocrevus, the company's top-selling drug.

Roche Diagnostics CEO Schinecker Will Succeed Schwan As A New Chapter Unfolds

The Swiss drug maker is preparing for a smooth transition in 2023, appointing 20-year Roche veteran and diagnostic chief Thomas Schinecker as its next chief executive as Severin Schwan becomes chairman.

Bad Omen Or Opportunity? Roche’s TIGIT Failure Hits Rivals Hard

After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146528

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel